<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308723</url>
  </required_header>
  <id_info>
    <org_study_id>BP25497</org_study_id>
    <nct_id>NCT01308723</nct_id>
  </id_info>
  <brief_title>A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (NexavarÂ®), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label study will assess the safety, efficacy and pharmacokinetics of RO5323441 in
      combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma
      previously untreated with systemic therapy. In the dose-finding Part I, cohorts of patients
      will receive escalating doses of RO5323441 intravenously (iv) every 2 weeks in combination
      with sorafenib 400 mg orally twice daily. In the exploratory Part II, patients will be
      randomized to receive either the previously established dose of RO5323441 iv every 2 weeks
      plus continuous oral sorafenib or sorafenib alone. Anticipated time on study treatment is
      until disease progression or unacceptable toxicity occurs. For patients in the sorafenib arm
      with disease progression crossover to combination treatment with RO5323441 will be allowed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I : Safety/dose-limiting toxicity: Incidence of adverse events</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Determination of recommended Part II dose</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Safety/tolerability: Incidence of adverse events</measure>
    <time_frame>up to 28 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RO5323441 in combination with sorafenib</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of sorafenib in combination with RO5323441</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarkers (DCE-Magnetic Resonance Imaging evaluations, Placental Growth Factor, Vascular Endothelial Growth Factor Receptors)</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: tumor assessments by Magnetic Resonance Imaging or Computed Tomography according to RECIST criteria</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on wound healing (skin biopsies)</measure>
    <time_frame>up to 40 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: additional anti-drug antibodies sampling after termination of study drug treatment</measure>
    <time_frame>2 and 4 months after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5323441</intervention_name>
    <description>escalating doses iv</description>
    <arm_group_label>Part I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5323441</intervention_name>
    <description>iv every 2 weeks</description>
    <arm_group_label>Part II (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>400 mg orally twice daily to once every other day</description>
    <arm_group_label>Part I</arm_group_label>
    <arm_group_label>Part II (A)</arm_group_label>
    <arm_group_label>Part II (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;/= 21 years of age

          -  Advanced or metastatic and/or unresectable hepatocellular carcinoma

          -  At least 1 measurable lesion according to RECIST criteria

          -  Primary tumor in situ (Expansion Cohort Part I, Part II)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Prior systemic treatment for metastatic hepatocellular carcinoma or patients who had
             tumor removed (Expansion Cohort Part I, Part II)

          -  Major surgery within previous 4 weeks or planned major surgical procedure during
             course of study

          -  Radiation therapy within 28 days prior to start of study treatment

          -  Serious non-healing wound, ulcer ore bone fracture

          -  History of uncontrolled seizures or encephalopathy within the last 6 months

          -  Current central nervous system (CNS) metastases or spinal cord compression

          -  History of gastrointestinal perforation or esophageal/gastric bleeding within 6 months
             prior to study enrollment

          -  History of another primary malignancy and off treatment for &lt;/= 3 years, except for
             non-melanoma skin cancer and carcinoma in situ of the cervix

          -  Patients with prior liver transplant

          -  Inadequately controlled hypertension or prior history of hypertensive crisis or
             hypertensive encephalopathy

          -  Active bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

